Results 201 to 210 of about 10,758 (225)

Immuno-neural mechanisms in gastrointestinal tumorigenesis: bridging inflammation, neural regulation, and therapeutic innovation. [PDF]

Front Immunol
Zhao Y, Sui JF, Wu DN, Chen M, Ni JX, Zhang Y, Xin SY, Fan MN.   +7 more
europepmc   +1 more source

Hypertension associated with systemic therapy for hepatocellular carcinoma and management strategies. [PDF]

Front Pharmacol
Li Y, Wang B, Zhang D, Xin Y, Wang X.
europepmc   +1 more source

The Neuroimmune Axis in Gastric Cancer: Bridging Neural Regulation, Tumor Microenvironment, and Immunotherapy. [PDF]

Oncol Res
Zhang F, Wang X, Shen X, Xiong P, Yang Y, Wang J.   +5 more
europepmc   +1 more source

Targeting regulatory T cells in the prostate cancer microenvironment: From mechanisms to therapeutics (Review). [PDF]

Mol Med Rep
Luo H.
europepmc   +1 more source

CTLA-4 and targeted immunotherapy-a key link in the systemic influence of periodontitis: a mini review. [PDF]

Front Dent Med
Thanigaimalai A, Ravindran DM, Balaji SK, Bhuvaneswari B, SriSanjhanaa C.   +4 more
europepmc   +1 more source

Histologic Features of Melanocytic Nevi Secondary to Melanoma Treatment With Immune Checkpoint Inhibitors. [PDF]

Cureus
Sohail N, Sohail A, Durrani S, Bilbaoa J, Abbud CA, Simpson B, Reyes Barron C.   +6 more
europepmc   +1 more source

Understanding genetic determinants of resistance to immune checkpoint blockers

Seminars in Cancer Biology, 2020
The advent of immune checkpoint blockers (ICB) has revolutionized patient outcome in many tumor types. However, only a minority of patients truly benefits from these therapies and displays a durable and robust anti-tumor response that translates into improved outcome.
Roman M Chabanon, Sophie Postel-Vinay, Sandrine Aspeslagh   +2 more
exaly   +5 more sources

Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers [PDF]

Clinical and Experimental Immunology, 2020
Summary Immune checkpoint blockers improve the overall survival of a limited number of patients among different cancers. Identifying pathways that influence the immunological and clinical response to treatment is critical to improve the therapeutic efficacy and predict clinical responses.
Marcelo Hill
exaly   +4 more sources

Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis

European Journal of Cancer, 2023
For patients with advanced thymic epithelial tumours (TET), there is no standard second-line treatment after platinum-based chemotherapy. Although immune checkpoint blockers (ICB) are a potential treatment strategy, their efficacy seems limited with an increased risk of immune-related adverse events (ir-AEs), thus hampering their application in daily ...
Benjamin Besse, Massimo Di Maio, Lizza Hendriks   +2 more
exaly   +5 more sources

Some of the next articles are maybe not open access.

Related searches:

Initial development of biosimilar immune checkpoint blockers using HEK293 cells

Protein Expression and Purification, 2020
Antibodies that block interaction of immune checkpoint receptors with its ligands have revolutionized the treatment of several cancers. Despite the success of this approach, the high cost has been restricted the use of this class of drugs. In this context, the development of biosimilar can be an important strategy for reducing prices and expanding ...
Michael Bernardes, Ramos, Anna Erika Vieira de, Araújo, Cristiane Pinheiro, Pestana, Ana Paula Dinis, Ano Bom, Renata Chagas, Bastos, Aline, de Almeida Oliveira, Patrícia Cristina, da Costa Neves, Haroldo Cid, da Silva Junior   +7 more
openaire   +2 more sources